Covered recipient · General Payments record
JUSTIN DOWLATSHAHI
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2019–2024
$572.25
- Reported across 25 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $323.79 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $115.74 | 7 |
| Lilly USA, LLC | $92.11 | 5 |
| Exact Sciences Corporation | $59.65 | 2 |
| Amgen Inc. | $40.73 | 3 |
| ABBVIE INC. | $15.56 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $15.56 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103657282 | CMS |
| Amgen Inc. | $13.92 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117241719 | CMS |
| Amgen Inc. | $13.48 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111565733 | CMS |
| Amgen Inc. | $13.33 | 08/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117241721 | CMS |
| Exact Sciences Corporation | $29.90 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114640752 | CMS |
| Exact Sciences Corporation | $29.75 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114640758 | CMS |
| Lilly USA, LLC | $20.66 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135111946 | CMS |
| Lilly USA, LLC | $19.75 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135090799 | CMS |
| Lilly USA, LLC | $20.44 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135115655 | CMS |
| Lilly USA, LLC | $15.01 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135111948 | CMS |
| Lilly USA, LLC | $16.25 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135111944 | CMS |
| Novo Nordisk Inc | $14.76 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097232485 | CMS |
| Novo Nordisk Inc | $17.67 | 02/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096954169 | CMS |
| Novo Nordisk Inc | $17.02 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096623522 | CMS |
| Novo Nordisk Inc | $15.89 | 06/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097559760 | CMS |
| Novo Nordisk Inc | $17.60 | 08/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096850136 | CMS |
| Novo Nordisk Inc | $17.10 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097397335 | CMS |
| Novo Nordisk Inc | $15.70 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096749750 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.